Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
This article was originally published in The Pink Sheet Daily
Executive Summary
After spending $257 million and pushing into Phase III trials for a rare thyroid cancer, Bristol-Myers Squibb ends its deal. Exelixis CEO George Scangos says: "There is no smoking gun."